Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
6.59
-0.09 (-1.35%)
Aug 28, 2026, 4:00 PM EDT - Market closed
Gyre Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 109.82 | 116.59 | 105.76 | 113.45 | 102.29 | |
Revenue Growth | -3.38% | 10.24% | -6.78% | 10.91% | - |
Cost of Revenue | 6.81 | 5.42 | 3.88 | 4.64 | 4.79 |
Gross Profit | 103.01 | 111.17 | 101.87 | 108.81 | 97.5 |
Selling, General & Admin | 90.4 | 85.98 | 73.62 | 75.82 | 71.61 |
Research & Development | 27.87 | 13.7 | 12.02 | 13.78 | 16.69 |
Operating Expenses | 118.27 | 99.68 | 85.64 | 89.6 | 88.29 |
Operating Income | -15.26 | 11.49 | 16.23 | 19.21 | 9.2 |
Interest & Investment Income | 1.43 | 1.75 | 1.55 | 1.04 | 0.73 |
Earnings From Equity Investments | -0.08 | -0.08 | -0.04 | -1.31 | -0.25 |
Currency Exchange Gain (Loss) | - | - | - | -1.5 | -4.9 |
Other Non Operating Income (Expenses) | -2.29 | 0.48 | 5.45 | -8.97 | 3.73 |
EBT Excluding Unusual Items | -16.2 | 13.64 | 23.18 | 8.48 | 8.51 |
Gain (Loss) on Sale of Assets | -0 | -0 | -0.07 | -3.34 | - |
Other Unusual Items | 0.8 | 0.8 | 0.1 | 1 | 0.9 |
Pretax Income | -22.29 | 14.44 | 23.22 | -76.97 | 9.41 |
Income Tax Expense | 3.38 | 4.56 | 5.32 | 8.52 | 5.1 |
Earnings From Continuing Operations | -25.67 | 9.88 | 17.9 | -85.48 | 4.31 |
Minority Interest in Earnings | 4.45 | -4.85 | -5.81 | -7.45 | -2.01 |
Net Income | -21.22 | 5.03 | 12.09 | -92.93 | 2.3 |
Net Income to Common | -19.91 | 5.03 | 12.09 | -92.93 | 2.3 |
Net Income Growth | - | -58.40% | - | - | - |
Shares Outstanding (Basic) | 94 | 89 | 85 | 66 | 64 |
Shares Outstanding (Diluted) | 94 | 103 | 102 | 66 | 76 |
Shares Change | -1.16% | 0.87% | 55.39% | -13.02% | - |
EPS (Basic) | -0.21 | 0.06 | 0.14 | -1.41 | 0.04 |
EPS (Diluted) | -0.22 | 0.02 | 0.05 | -1.41 | 0.03 |
EPS Growth | - | -53.23% | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | -6.11 | -0.18 | -5.96 | 17.38 | 5.69 |
Free Cash Flow Per Share | -0.07 | -0.00 | -0.06 | 0.26 | 0.07 |
Gross Margin | 93.80% | 95.36% | 96.33% | 95.91% | 95.31% |
Operating Margin | -13.90% | 9.86% | 15.35% | 16.93% | 9.00% |
Profit Margin | -18.13% | 4.31% | 11.43% | -81.92% | 2.25% |
Free Cash Flow Margin | -5.56% | -0.15% | -5.63% | 15.32% | 5.56% |
EBITDA | -12.13 | 14.01 | 17.82 | 20.33 | 10.33 |
EBITDA Margin | -11.05% | 12.02% | 16.85% | 17.92% | 10.10% |
D&A For EBITDA | 3.13 | 2.52 | 1.59 | 1.11 | 1.13 |
EBIT | -15.26 | 11.49 | 16.23 | 19.21 | 9.2 |
EBIT Margin | -13.90% | 9.86% | 15.35% | 16.93% | 9.00% |
Effective Tax Rate | - | 31.56% | 22.91% | - | 54.16% |